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Introduction {#ehf212109-sec-0004}
============

Over 50% of patients with symptomatic heart failure (HF) experience HF with preserved ejection fraction (HFpEF).[1](#ehf212109-bib-0001){ref-type="ref"} The advent of pharmacologic management promises improved left ventricular diastolic function[2](#ehf212109-bib-0002){ref-type="ref"} and a reduced rate of hospitalization in HFpEF patients.[3](#ehf212109-bib-0003){ref-type="ref"} Regular physical activity and structured exercise training (ET) are a cornerstone of non‐pharmacological management in HF patients.[4](#ehf212109-bib-0004){ref-type="ref"}, [5](#ehf212109-bib-0005){ref-type="ref"} ET was found to be effective in improving cardiorespiratory fitness[6](#ehf212109-bib-0006){ref-type="ref"}, [7](#ehf212109-bib-0007){ref-type="ref"} and dimensions of quality of life in patients with HFpEF.[8](#ehf212109-bib-0008){ref-type="ref"} Strikingly, ET as a mean of cardiovascular rehabilitation has also been associated to improved left ventricular diastolic function in patients with reduced[6](#ehf212109-bib-0006){ref-type="ref"} and preserved[7](#ehf212109-bib-0007){ref-type="ref"} ejection fraction.

Recently, a new paradigm for HFpEF has been proposed, which identifies a systemic pro‐inflammatory state induced by comorbidities as the cause of myocardial structural and functional alterations.[9](#ehf212109-bib-0009){ref-type="ref"} The pleiotropic stimulus of ET leaves room for mechanistic considerations regarding the beneficial effect of ET in HFpEF, including anti‐inflammation[10](#ehf212109-bib-0010){ref-type="ref"} and reduced neuro‐hormonal activation.[11](#ehf212109-bib-0011){ref-type="ref"} Hormonal alterations may play a pivotal role in mediating this process. Inflammatory cytokines are associated with the progression of cardiac hypertrophy,[12](#ehf212109-bib-0012){ref-type="ref"} and low cytokine levels may be protective for myocytes, whereas persistently high levels are detrimental.[13](#ehf212109-bib-0013){ref-type="ref"}, [14](#ehf212109-bib-0014){ref-type="ref"} The growth hormone‐releasing peptide ghrelin has been mainly attributed to the metabolic system and changes in body composition. Noteworthy, ghrelin was found to inhibit apoptosis of cardiomyocytes and endothelial cells *in vitro*,[15](#ehf212109-bib-0015){ref-type="ref"} decreases blood pressure, and increases cardiac output.[16](#ehf212109-bib-0016){ref-type="ref"} It has been suggested that repeated administration of ghrelin may improve left ventricular function, exercise capacity, and muscle wasting and significantly decrease plasma norepinephrine in patients with HF.[17](#ehf212109-bib-0017){ref-type="ref"} In older adults, ET was not only related to inflammatory state but also modified ghrelin.[18](#ehf212109-bib-0018){ref-type="ref"} Thus, the encouraging mechanistic effects of ET on myocardial structural and functional alterations may be attributable to endogenously altered ghrelin and hormonal levels.

The purpose of the present *post hoc* analysis of the Ex‐DHF‐P trial[7](#ehf212109-bib-0007){ref-type="ref"} was to investigate the impact of structured and supervised ET on ghrelin, related adipokines, markers of inflammation, and neuro‐hormonal activation in the setting of a prospective, controlled, randomized multi‐centre trial in patients with HFpEF. ET improved exercise capacity and physical dimensions of quality of life in HFpEF. This benefit was associated with atrial reverse remodelling and improved left ventricular diastolic function.[7](#ehf212109-bib-0007){ref-type="ref"}

Methods {#ehf212109-sec-0005}
=======

Study design, sample size {#ehf212109-sec-0006}
-------------------------

This is a secondary analysis of Ex‐DHF‐P. To date, the trial is the largest, prospective, multicentre, randomized‐controlled trial on ET in patients with HFpEF. Of the originally 71 patients screened for the trial, 67 were included, and 64 were analysed in the primary study.[7](#ehf212109-bib-0007){ref-type="ref"} Supervised structured endurance/resistance ET on top of usual care (UC) was tested against UC alone. ET improved exercise capacity and physical dimensions of quality of life in HFpEF. This benefit was associated with atrial reverse remodelling and improved left ventricular diastolic function.

Laboratory biomarker testing {#ehf212109-sec-0007}
----------------------------

Blood sampling in Ex‐DHF‐P was performed according to protocol under standardized conditions. Sampling in one respective patient was performed at the same time of day, preferably fasting in the morning, to eliminate the influence of circadian variation and after a 20 min supine resting period. All samples were immediately centrifuged and stored at −80 °C. Laboratory marker analysis was performed centrally and *post hoc*. For assessment of ghrelin, a commercially available radio‐immuno‐assay (ghrelin RIA‐Kit, R90, Mediagnost GmbH, Reutlingen, Germany) was used. Solid‐phase ELISAs were used for assessment of adiponectin (human adiponectin, DRP 300, R&D Systems Inc., Minneapolis, MN, USA), Leptin (human leptin, DLP 00, R&D), interleukin‐1‐beta (human IL‐1*ß*, HSLB 00C, R&D), interleukin‐6 (human IL‐6, HS 600B R&D), interleukin‐10 (human IL‐10, HS 100B, R&D), and tumour necrosis factor alpha (human TNF alpha, HSTA 00D, R&D). Aforementioned assessments were performed according to the respective manual by an experienced and certified laboratory technician at Ulm University Medical Centre (Department for Internal Medicine II, Cardiology, Albert‐Einstein‐Allee 23, 89081 Ulm, Germany). MR‐proANP, MR‐proADM, CT‐proET1, and CT‐proAVP (BRAHMS Kryptor Assays, Thermo Fisher Scientific Clinical Diagnostics B · R · A · H · M · S GmbH, Hennigsdorf, Germany) were measured by time‐resolved amplified cryptate emission technology by a certified reference laboratory (through Thermo Fisher Scientific Clinical Diagnostics BRAHMS).

Ethics {#ehf212109-sec-0008}
------

The German Health Authorities and the ethics committees at each centre approved the study. Written informed consent was obtained from all patients before any study‐related procedure was performed.

Statistics {#ehf212109-sec-0009}
----------

Changes of the level of the investigated biomarkers were assessed by linear model with follow‐up measurement as dependent variable and treatment group as fixed factor. The model was adjusted by the baseline value. To specify the additional impact of ghrelin, we computed several multivariate models for the change of ghrelin---computed as follow‐up value minus baseline value. We transformed ghrelin for all analysis to the logarithmic scale. Metric data were shown as mean ± SD. For skewed distributed laboratory data, presented at baseline and follow‐up, data were shown by median and interquartile range (IQR). Nominal or categorical data are presented with *n* and %. Analyses were performed according to the intent‐to‐treat principle. The software used for statistical analyses was R 3.0.3 (cran.r‐project.org).

Results {#ehf212109-sec-0010}
=======

The primary results of Ex‐DHF‐P have been reported elsewhere.[7](#ehf212109-bib-0007){ref-type="ref"} Of the 64 patients available for analysis, two patients were excluded for quality concerns with blood serum samples. Twenty‐six (42%) of the 62 analysed patients were male. *Table* [1](#ehf212109-tbl-0001){ref-type="table-wrap"} shows baseline characteristics of the study population stratified by high vs. low ghrelin serum levels according to a median split (median ghrelin 928 pg/mL) of data. Age did not differ between groups, whereas significantly more women showed higher ghrelin levels. Waist circumferences were higher and obesity more prevalent in the group with lower ghrelin levels. In regard to demographics, risk factors, echocardiographic structure, cardiopulmonary function, quality of life, and treatment subjects were comparable in both groups.

###### 

Baseline characteristics of study population stratified by a ghrelin median split

  Ghrelin at baseline no. of subjects                                                 Total (*n* = 62)    Low ghrelin (*n* = 31)   High ghrelin (*n* = 31)   *P*‐value
  ----------------------------------------------------------------------------------- ------------------- ------------------------ ------------------------- -----------
  Demographics                                                                                                                                               
  Age (years)                                                                         64.4 ± 7.2          63.2 ± 7.5               65.6 ± 6.7                0.17
  Sex (female)                                                                        36 (58)             11 (35)                  25 (81)                   0.001
  Heart rate (bpm)                                                                    64 ± 10             66 ± 11                  62 ± 9                    0.20
  Systolic BP (mmHg)                                                                  150 ± 21            149 ± 21                 150 ± 21                  0.91
  Diastolic BP (mmHg)                                                                 85 ± 11             84 ± 12                  87 ± 10                   0.22
  Waist (cm)                                                                          99 ± 13             104 ± 12                 94 ± 13                   0.004
  New York Heart Association (NYHA) functional class                                  0.73                                                                   
  II                                                                                  52 (84)             25 (81)                  27 (87)                   
  III                                                                                 10 (16)             6 (19)                   4 (13)                    
  Risk factors                                                                                                                                               
  Arterial hypertension                                                               54 (87)             26 (84)                  28 (90)                   0.71
  Hyperlipidaemia                                                                     29 (47)             15 (48)                  14 (45)                   1.00
  Diabetes mellitus                                                                   9 (15)              4 (13)                   5 (16)                    1.00
  Obesity (BMI ≥ 30 kg/m^2^)                                                          32 (52)             21 (68)                  11 (35)                   0.021
  (BMI \> 25 kg/m^2^)                                                                 55 (89)             28 (90)                  27 (87)                   1.00
  Abnormal waist (\>102 cm (male); \>88 cm (female))                                  38 (61)             19 (61)                  19 (61)                   1.00
  Smoker                                                                              6 (10)              4 (13)                   2 (6)                     0.67
  Cardiac structure and function                                                                                                                             
  Left ventricular ejection fraction (LVEF) (%)                                       67 ± 7              67 ± 7                   68 ± 6                    0.40
  Left atrial volumen index (LAVI) (mL/m^2^)                                          27.7 ± 8.0          29.1 ± 8.8               26.2 ± 7.1                0.16
  Left ventricular mass index (LVMI) (g/m^2^)                                         134.1 ± 34.2        132.8 ± 33.7             135.4 ± 35.2              0.77
  E/e′ lateral                                                                        9.7 ± 2.8           9.8 ± 2.9                9.5 ± 2.8                 0.70
  E/e′ medial                                                                         12.9 ± 3.7          13.1 ± 4.1               12.7 ± 3.2                0.69
  e′ lateral (mm)                                                                     7.5 ± 2.0           7.5 ± 2.1                7.5 ± 1.9                 1.00
  e′ medial (mm)                                                                      5.6 ± 1.3           5.6 ± 1.2                5.5 ± 1.5                 0.92
  VO^2^ max                                                                           16.2 ± 4.8          16.3 ± 5.2               16.0 ± 4.5                0.84
  Watt max                                                                            114 ± 37            123 ± 41                 105 ± 31                  0.07
  6MWD (m)                                                                            544 ± 88            546 ± 101                543 ± 74                  0.89
  Laboratory                                                                                                                                                 
  Haemoglobin (mmol/L)                                                                8.9 (8.3--9.5)      9.2 (8.8--9.6)           8.6 (8.3--9.2)            0.11
  NT‐proBNP (pg/mL)                                                                   124 (78--183)       118 (62--157)            128 (80--210)             0.11
  Sens. CRP (mg/L)                                                                    1.83 (0.93--3.63)   1.85 (0.78--3.71)        1.82 (0.98--3.04)         0.56
  Treatment                                                                                                                                                  
  Angiotensin converting enzyme inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB)   41 (67)             19 (63)                  22 (71)                   0.59
  *β*‐Blocker                                                                         31 (51)             17 (57)                  14 (45)                   0.45
  Mineralcorticoid Receptor Antagonist (MRB)                                          2 (3)               1 (3)                    1 (3)                     1.00
  Diuretic                                                                            26 (43)             13 (43)                  13 (42)                   1.00
  Lipid lowering drug                                                                 16 (26)             10 (33)                  6 (19)                    0.25
  Uric acid lowering drug                                                             6 (10)              3 (10)                   3 (10)                    1.00
  Quality of life                                                                                                                                            
  SF‐36 physical sum score                                                            42.8 ± 9.7          44.2 ± 9.3               41.3 ± 10.0               0.26
  SF‐36 mental sum score                                                              49.5 ± 10.6         48.8 ± 10.7              50.3 ± 10.6               0.61
  SF‐36 physical functioning scale                                                    66.8 ± 21.0         68.9 ± 19.7              64.6 ± 22.4               0.43
  Patient Health Questionnaire (PHQ) sum score                                        6.2 ± 5.6           6.6 ± 6.1                5.8 ± 5.1                 0.62

BMI, body mass index; BP, blood pressure.

Values are *n* (%), mean ± SD, or median (interquartile range) tests are *χ* ^2^ for index or nominal variables tauB for ordinal and analysis of variance for metric measurements.

Adiponectin levels tended to be higher in patients with higher ghrelin levels \[median adiponectin levels 8828 ng/mL (IQR 6270--13637) in high ghrelin and 6417 ng/mL (IQR 4068--9167) in low ghrelin, *P* = 0.012\]. Levels of TNF‐*α*, IL‐1*ß*, IL‐6, IL‐10, MR‐proANP, MR‐proADM, CT‐proET1, and CT‐proAVP were comparable in the setting of high vs. low ghrelin (*P* \> 0.05).

Aside from significantly higher values for MR‐proANP in the UC group at baseline (*P* = 0.007), no significant (*P* \> 0.05) differences between the respective treatment groups was observed at the respective time‐point (*Table* [2](#ehf212109-tbl-0002){ref-type="table-wrap"}). Overall changes and changes over the course of biomarkers in the respective treatments groups are displayed in *Table* [3](#ehf212109-tbl-0003){ref-type="table-wrap"}. In summary, we observed a significant change in ghrelin. Ghrelin increased significantly under ET. This shift in ghrelin was especially pronounced in the setting of low ghrelin levels at baseline in the ET intervention group (*Figure* [1](#ehf212109-fig-0001){ref-type="fig"}). With regard to the increase in ghrelin, analysis of covariance models for change in ghrelin and ratio of geometric means are shown in *Table* [4](#ehf212109-tbl-0004){ref-type="table-wrap"}. Among baseline ghrelin values, ET and higher adiponectin levels (*Figure* [2](#ehf212109-fig-0002){ref-type="fig"}) in the ET group significantly contributed to the model.

###### 

Laboratory values at baseline and follow‐up

  Time point                          Baseline                Follow‐up                                                                                       
  ----------------------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- -----------------------
  Ghrelin \[pg/mL\]                   928 (755--1156)         833 (755--1114)         988 (758--1166)         1013 (813--1182)        913 (796--1027)         1092 (852--1203)
  Leptin \[pg/mL\]                    22 579 (7106--40 487)   28 379 (7768--50 159)   20 326 (6726--36 376)   22 487 (8979--43 155)   33 774 (9536--53 063)   18 320 (9106--34 361)
  Adiponectin \[ng/mL\]               7596 (4328--11 148)     8777 (4162--11 704)     7590 (4427--10 782)     7028 (4868--11 345)     7987 (5146--11 246)     6647 (4211--11 002)
  TNF‐*α* \[pg/mL\]                   1.66 (1.11--2.45)       1.93 (1.40--2.33)       1.54 (1.07--2.55)       2.03 (1.40--3.07)       2.30 (1.69--3.59)       1.95 (1.37--2.57)
  IL‐1*β* \[pg/mL\]                                                                                                                                           
  Below detection cut‐off             36 (58.06)              10 (52.63)              26 (60.47)              54 (87.10)              17 (89.47)              37 (86.05)
  Above detection cut‐off             26 (41.94)              9 (47.37)               17 (39.53)              8 (12.90)               2 (10.53)               6 (13.95)
  IL‐1*β* \[pg/mL\] (if measurable)   0.20 (0.11--0.52)       0.18 (0.14--0.38)       0.22 (0.11--0.59)       0.09 (0.06--0.56)       0.31 (0.19--0.43)       0.08 (0.06--0.46)
  IL‐6 \[pg/mL\]                      1.57 (1.13--2.48)       1.61 (0.96--2.15)       1.56 (1.26--2.63)       1.44 (1.00--2.60)       1.42 (1.23--2.02)       1.45 (0.91--2.84)
  IL‐10 \[pg/mL\]                                                                                                                                             
  Below detection cut‐off             31 (50.00)              13 (68.42)              18 (41.86)              42 (67.74)              12 (63.16)              30 (69.77)
  Above detection cut‐off             31 (50.00)              6 (31.58)               25 (58.14)              20 (32.26)              7 (36.84)               13 (30.23)
  IL‐10 \[pg/mL\] (if measurable)     8.42 (4.26--16.70)      9.10 (5.92--15.49)      8.16 (4.13--16.28)      1.80 (0.96--4.12)       0.61 (0.44--1.48)       2.22 (1.64--6.02)
  MR‐proANP \[pmol/L\]                96 (78--129)            118 (98--148)           91 (68--114)            91 (71--124)            97 (75--136)            86 (61--108)
  MR‐proADM \[nmol/L\]                0.52 (0.48--0.66)       0.52 (0.46--0.64)       0.52 (0.49--0.66)       0.57 (0.50--0.72)       0.57 (0.52--0.68)       0.58 (0.49--0.73)
  CT‐proET1 \[nmol/L\]                55.0 (51.0--63.8)       56.0 (51.0--63.5)       55.0 (50.5--64.0)       58.0 (51.0--66.8)       57.0 (50.5--70.0)       59.0 (52.0--66.5)
  CT‐proAVP \[pmol/L\]                4.10 (2.45--7.20)       3.40 (2.60--6.45)       4.10 (2.45--7.95)       3.98 (2.48--6.17)       3.73 (2.21--5.89)       4.15 (2.60--6.38)

TNF, tumour necrosis factor.

Values median (interquartile range) resp. *N* (%).

Usual care with significantly (*P* \< 0.05) higher values for MR‐proANP at baseline. A selection bias is assumed.

###### 

Change of endogenous biomarkers over 12 weeks

  Coefficient            Ratio of geometric mean \[95%CI\]   *P*‐value
  ---------------------- ----------------------------------- -----------
  Ghrelin                                                    
  (Intercept)            4.23 \[2.10--8.54\]                 \<0.001
  Baseline value         1.73 \[1.61--1.86\]                 \<0.001
  Treatment group (ET)   1.09 \[1.02--1.17\]                 0.013
  Leptin                                                     
  (Intercept)            6.54 \[2.59--16.55\]                \<0.001
  Baseline value         1.78 \[1.67--1.90\]                 \<0.001
  Treatment group (ET)   0.85 \[0.68--1.06\]                 0.15
  Adiponectin                                                
  (Intercept)            6.27 \[1.76--22.26\]                0.005
  Baseline value         1.74 \[1.58--1.92\]                 \<0.001
  Treatment group (ET)   0.89 \[0.74--1.07\]                 0.20
  TNF‐*α*                                                    
  (Intercept)            2.06 \[1.56--2.71\]                 \<0.001
  Baseline value         1.26 \[1.10--1.44\]                 0.001
  Treatment group (ET)   0.77 \[0.57--1.04\]                 0.09
  IL‐6                                                       
  (Intercept)            1.13 \[0.77--1.66\]                 0.51
  Baseline value         1.84 \[1.53--2.22\]                 \<0.001
  Treatment group (ET)   0.83 \[0.53--1.30\]                 0.41
  IL‐10                                                      
  (Intercept)            0.11 \[0.01--2.04\]                 0.12
  Baseline value         1.41 \[0.80--2.49\]                 0.20
  Treatment group (ET)   10.02 \[0.88--114.09\]              0.06
  MR‐proANP                                                  
  (Intercept)            1.06 \[0.35--3.16\]                 0.92
  Baseline value         1.94 \[1.66--2.27\]                 \<0.001
  Treatment group (ET)   1.08 \[0.89--1.31\]                 0.44
  MR‐proADM                                                  
  (Intercept)            1.15 \[1.05--1.25\]                 0.004
  Baseline value         2.14 \[1.97--2.34\]                 \<0.001
  Treatment group (ET)   1.00 \[0.94--1.07\]                 0.99
  CT‐proET1                                                  
  (Intercept)            1.24 \[0.60--2.57\]                 0.55
  Baseline value         1.93 \[1.71--2.19\]                 \<0.001
  Treatment group (ET)   1.03 \[0.96--1.10\]                 0.47
  CT‐proAVP                                                  
  (Intercept)            1.14 \[0.90--1.45\]                 0.26
  Baseline value         1.80 \[1.64--1.97\]                 \<0.001
  Treatment group (ET)   1.10 \[0.91--1.33\]                 0.34

ET, exercise training; TNF, tumour necrosis factor; UC, usual care.

Tabulated is for each measurement the ratio of geometric mean and *P*‐values of the group difference between the two arms \[UC vs. ET interpretation: the ratio of the geometric mean value of ghrelin (at baseline) for UC vs. ET is 1.73 (95% CI: 1.61--1.86)\].

![Change of ghrelin over 12 weeks. UC, usual care; ET, exercise training.](EHF2-4-56-g001){#ehf212109-fig-0001}

###### 

ANCOVA models for change in ghrelin over 12 weeks

  Coefficient                                                                                                            Ratio of geometric mean \[95%CI\]   *P*‐value
  ---------------------------------------------------------------------------------------------------------------------- ----------------------------------- -----------
  Change of ghrelin                                                                                                                                          
  Model 1: ... by baseline ghrelin                                                                                                                           
  (Intercept)                                                                                                            4.31 \[2.07--8.96\]                 \<0.001
  Ghrelin (baseline)                                                                                                     0.87 \[0.81--0.94\]                 \<0.001
  Model 2: ... by baseline ghrelin adjusted for treatment group                                                                                              
  (Intercept)                                                                                                            4.23 \[2.10--8.54\]                 \<0.001
  Ghrelin (baseline)                                                                                                     0.86 \[0.81--0.93\]                 \<0.001
  Exercise training                                                                                                      1.09 \[1.02--1.17\]                 0.013
  Model 3: ... by baseline ghrelin adjusted for treatment group and adiponectin (high)                                                                       
  (Intercept)                                                                                                            4.18 \[2.02--8.62\]                 \<0.001
  Ghrelin (baseline)                                                                                                     0.87 \[0.80--0.93\]                 \<0.001
  Exercise training                                                                                                      1.09 \[1.02--1.17\]                 0.014
  Adiponectin (high)                                                                                                     1.01 \[0.94--1.07\]                 0.86
  Model 4: ... by baseline ghrelin adjusted for treatment group, interaction \[exercise training: adiponectin (high)\]                                       
  (Intercept)                                                                                                            4.37 \[2.18--8.74\]                 \<0.001
  Ghrelin (baseline)                                                                                                     0.87 \[0.81--0.93\]                 \<0.001
  Exercise training                                                                                                      1.01 \[0.92--1.11\]                 0.79
  Adiponectin (high)                                                                                                     0.90 \[0.81--1.01\]                 0.06
  Exercise training: adiponectin (high)                                                                                  1.15 \[1.01--1.32\]                 0.035

ANCOVA, analysis of covariance.

Tabulated is per model the ratio of geometric means and the *P‐*value of the ANCOVA test.

![Change of ghrelin over 12 weeks by treatment group and baseline adiponectin. UC, usual care; ET, exercise training.](EHF2-4-56-g002){#ehf212109-fig-0002}

Discussion {#ehf212109-sec-0011}
==========

This study investigates the effect of ET on ghrelin levels and other biomarkers in the setting of HFpEF. We report a significant impact of ET on endogenous ghrelin in this randomized, controlled trial. ET clearly increased ghrelin levels. Patients with lower ghrelin levels at baseline indeed experienced a more pronounced increase in ghrelin under a training intervention. The increase in ghrelin was related to higher adipokine levels at baseline. Of note, beneficial effects in patients with cardiovascular disease, especially HF, have previously been attributed to an altered expression of ghrelin. Further, we investigated the trajectories of adipokines, inflammatory and anti‐inflammatory markers, and surrogates of neuro‐hormonal activation in the EX‐DHF‐P trial. In the current analysis (*n* = 62), general findings in cardiac structure and surrogate markers of HFpEF (*Table* [1](#ehf212109-tbl-0001){ref-type="table-wrap"}) are in line with the primary results of Ex‐DHF‐P.[7](#ehf212109-bib-0007){ref-type="ref"}

Ghrelin {#ehf212109-sec-0012}
-------

In this trial, the median baseline ghrelin level was 928 pg/mL. A clinically described ghrelin reference value for normal weight, control subjects is considered to be between 520 and 700 pg/mL. Makovey *et al*.[19](#ehf212109-bib-0019){ref-type="ref"} reported women to have higher ghrelin levels than men and found age to be a significant predictor of ghrelin levels after adjustment for gender, fat mass, and body size. Ghrelin levels are reportedly lower in individuals with a higher body weight.[20](#ehf212109-bib-0020){ref-type="ref"} Hence, we interpret our observation of differences in percentages of women and obese subjects in subgroups with higher vs. lower ghrelin levels as confirming the literature. Interestingly, Gibas‐Dorna *et al*.[20](#ehf212109-bib-0020){ref-type="ref"} reported significantly lower ghrelin levels in patients with hypertension when compared with controls. While we did not observe a difference in regard to blood pressure, this finding is of note when considering the left‐ventricular hypertrophy, diastolic dysfunction, and HFpEF continuum.

In this analysis, we evaluate the effect of ET on endogenous ghrelin levels in the setting of HFpEF. Under standardized conditions of a clinical trial, we observed a significant change of ghrelin over time. This change was seen in the ET group with a trend for change in the group with higher ghrelin levels and a clear change in the group with lower ghrelin levels (*Figure* [1](#ehf212109-fig-0001){ref-type="fig"}). Analysis of covariance modelling identified a marked ratio of geometric to be due to ET (*Table* [4](#ehf212109-tbl-0004){ref-type="table-wrap"}). Adiponectin was found to play an additional role in this setting (*Table* [4](#ehf212109-tbl-0004){ref-type="table-wrap"}). We interpret the currently observed increase in endogenous ghrelin levels under ET to be consistent with the alterations observed in studies in older adults[18](#ehf212109-bib-0018){ref-type="ref"} but consider it to may have additional clinical consequences in the setting of HF. Animal data suggest that endogenous ghrelin plays a crucial role in attenuating pressure overload‐induced cardiac hypertrophy and diastolic dysfunction.[21](#ehf212109-bib-0021){ref-type="ref"} Mao *et al*.[21](#ehf212109-bib-0021){ref-type="ref"} discuss these effects because of the activation of a cholinergic anti‐inflammatory pathway. By simultaneously evoking sympathetic inhibition and parasympathetic activation, ghrelin is considered to be effective against cardiovascular diseases.[21](#ehf212109-bib-0021){ref-type="ref"} Given that ghrelin was found to inhibit apoptosis of cardiomyocytes and endothelial cells *in vitro*,[15](#ehf212109-bib-0015){ref-type="ref"} it decreases blood pressure and increases cardiac output.[16](#ehf212109-bib-0016){ref-type="ref"} Nagaya *et al*. have previously suggested that repeated administration of ghrelin may improve left ventricular function, exercise capacity, and reduce muscle wasting in patients with HF. Because the relevance of sarcopenia in the clinical picture of HF[22](#ehf212109-bib-0022){ref-type="ref"} is growing and approximately 20% of HF patients with an average age of nearly 70 years may meet the criteria for diagnosing sarcopenia,[23](#ehf212109-bib-0023){ref-type="ref"} ghrelin may be an interesting treatment strategy to tackle the wasting continuum in HF.[24](#ehf212109-bib-0024){ref-type="ref"}

In a meta‐analysis on the effect of ghrelin on mortality and cardiovascular outcomes in experimental rat and mouse models of HF, Khatib *et al*.[25](#ehf212109-bib-0025){ref-type="ref"} consider the existing data to provide suggestive evidence that ghrelin may lower the risk of mortality and improve cardiovascular outcomes. In this work, we show that non‐pharmacologic HF management with regular physical activity and structured ET has the potential to alter endogenous ghrelin levels.

Due to statistical limitations in the present analysis, we refrained from assessing associations of the change of blood values and change in endpoint variables of the Ex‐DHF‐P study (e.g. E/e′ ratio, VO2max, LAVI, and SF‐36 physical functioning scale). However, future analyses in larger, prospective cohorts like the currently recruiting *Exercise Training in Diastolic Heart Failure Trial* may close this gap and allow for a more subtle pathophysiological evaluation of ghrelin\'s role.

Adipokines {#ehf212109-sec-0013}
----------

Leptin, as an adipocyte‐derived hormone, links nutritional status with neuroendocrine and immune functions, that is, by affecting IL‐1 and TNF‐*α*. Leptin has the potential to influence basal metabolism and angiogenesis. In the present analysis, we did observe an overall change in ghrelin between baseline and follow‐up, but not in regard to UC or ET.

The hormone adiponectin is secreted by adipose tissue. Adiponectin levels tended to be higher in patients with higher ghrelin levels. In this analysis, we report the effect of ET on change in ghrelin in patients with higher baseline adpionectin levels (*P* = 0.035). While body mass index did not change in either treatment group in the Ex‐DHF‐P trial,[7](#ehf212109-bib-0007){ref-type="ref"} fat mass and detailed body composition assessments were unfortunately not available in our patients. Levels of the hormone are previously shown to be inversely correlated with body fat percentage in adults.[26](#ehf212109-bib-0026){ref-type="ref"} Adiponectin is known to suppress TNF‐*α* production and to possess direct anti‐inflammatory effects. Hence, one may hypothesize the observed ET ghrelin*--*adipokine interaction to document physiologic pathways that may bear additional effects in diastolic HF.

Inflammatory and anti‐inflammatory markers {#ehf212109-sec-0014}
------------------------------------------

Higher levels of TNF‐*α* have been reported and debated in severe chronic HF.[27](#ehf212109-bib-0027){ref-type="ref"} In this study, we did observe a significant overall change in regard to TNF‐*α* and IL‐6 (*P* \< 0.05), but not in regard to treatment group. In fact, TNF‐*α* may play a role in a systemic pro‐inflammatory state, which has been suggested as a mechanism in HFpEF.[9](#ehf212109-bib-0009){ref-type="ref"} In their systematic review, Smart *et al.* [28](#ehf212109-bib-0028){ref-type="ref"} suggested that physical exercise employing ≥5 sessions per week may be most likely to reduce serum levels of TNF‐*α* in HF patients. In this analysis, we did not observe an analogue finding. Further, in regard to IL‐1*ß* and IL‐10, no relevant trajectory was observed. This may be explained by a marked number of samples with measured values below cut‐off thresholds, indicating a generally low inflammatory state of the present HF population.

Neuro‐hormonal activation {#ehf212109-sec-0015}
-------------------------

NT‐proBNP levels were reported to be similar at baseline in the respective treatment groups and did not change throughout Ex‐DHF‐P trial.[7](#ehf212109-bib-0007){ref-type="ref"} In regard to novel markers of neuro‐hormonal activation, we documented overall changes in MR‐proANP, MR‐proADM, CT‐proET1, and CT‐proAVP in this analysis. We observed significantly higher MR‐proANP levels in the UC group as compared with ET at baseline and assume a selection bias to explain this finding. Aside from this, MR‐proADM, CT‐proET1, and CT‐proAVP were comparable in the respective treatment groups at baseline and follow‐up. We did not observe a significant treatment interaction in the markers of neuro‐hormonal activation.

Exercise training confers benefit in terms of enhancements in exercise capacity and health‐related quality of life[29](#ehf212109-bib-0029){ref-type="ref"} in HFpEF patients. The processes behind better exercise capacity are complex and tend to reduce the level of muscle atrophy, inflammation, and catabolic/anabolic imbalance through molecular mechanisms.[30](#ehf212109-bib-0030){ref-type="ref"} The present analysis allows for a glance at the hormonal alterations that may play a pivotal role in mediating the underlying process.

Limitations {#ehf212109-sec-0016}
===========

This analysis is limited in its exploratory, secondary, *post hoc* character. Ex‐DHF‐P was a multicentre trial with a relatively small number of mildly affected, middle‐aged patients in short‐term follow‐up. The study was not primarily designed to address ghrelin, other endogenous biomarkers, and their interactions and not adequately powered to allow for definite conclusions. The reported results could hence be a statistical phenomenon, not only because the control group is considerably smaller than the ET group and therefore an identical effect in the control group had a lower chance to reach statistical significance than in the ET group. Therefore, future studies with an adequately powered sample size, a broader population with a wider range of stages of HFpEF, and long‐term follow‐up are necessary. The ongoing, larger Ex‐DHF study (recruitment completed) will allow for such analysis.

Conclusions {#ehf212109-sec-0017}
===========

This study investigates the effect of ET on endogenous ghrelin levels, and other biomarkers in the setting of HFpEF. ET tended to increase ghrelin levels in Ex‐DHF‐P. This increase was especially pronounced in patients with higher baseline adiponectin levels. We documented multiple, not‐treatment‐related changes in other biomarker trajectories in the setting of HFpEF. While suggestive data on the effects in patients with HF have been previously attributed to an altered expression of ghrelin, future trials are urgently needed to address the potential role of ghrelin, interactions, and clinically meaningful surrogate parameters in this setting.
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